MiNEN, amphicrine carcinomas, and conventional carcinomas with neuroendocrine differentiation: diagnostic criteria, open questions, and future perspectives.
Moritz Jesinghaus, Maxime Philipp Schmitt, Sebastian Foersch, Björn Konukiewitz
{"title":"MiNEN, amphicrine carcinomas, and conventional carcinomas with neuroendocrine differentiation: diagnostic criteria, open questions, and future perspectives.","authors":"Moritz Jesinghaus, Maxime Philipp Schmitt, Sebastian Foersch, Björn Konukiewitz","doi":"10.1007/s00428-025-04241-z","DOIUrl":null,"url":null,"abstract":"<p><p>Mixed neuroendocrine and non-neuroendocrine neoplasms (MiNEN) represent a heterogeneous group of bidirectionally differentiated epithelial malignancies that are, in most cases, highly aggressive. They are defined by the presence of morphologically distinct, yet clonally related, neuroendocrine and non-neuroendocrine components, each comprising at least 30% of the tumor mass according to current guidelines. Tumors that fall within the differential diagnostic spectrum of MiNEN include amphicrine carcinomas-characterized by the co-expression of neuroendocrine and non-neuroendocrine features within the same tumor cell-as well as conventional carcinomas that lack neuroendocrine morphology but exhibit immunohistochemical expression of neuroendocrine markers. However, these entities do not fulfill the current diagnostic criteria for MiNEN. In this review, we aim to outline the current diagnostic framework for MiNEN and examine the conceptual and classification boundaries of amphicrine carcinomas and conventional carcinomas with aberrant neuroendocrine marker expression in relation to what is presently defined as a MiNEN. In addition, we highlight key unresolved questions that should be addressed in future guidelines to streamline the diagnostic process and improve consistency. Finally, we provide an outlook on emerging technologies and future perspectives that may further refine the classification and clinical management of these complex neoplasms.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-025-04241-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Mixed neuroendocrine and non-neuroendocrine neoplasms (MiNEN) represent a heterogeneous group of bidirectionally differentiated epithelial malignancies that are, in most cases, highly aggressive. They are defined by the presence of morphologically distinct, yet clonally related, neuroendocrine and non-neuroendocrine components, each comprising at least 30% of the tumor mass according to current guidelines. Tumors that fall within the differential diagnostic spectrum of MiNEN include amphicrine carcinomas-characterized by the co-expression of neuroendocrine and non-neuroendocrine features within the same tumor cell-as well as conventional carcinomas that lack neuroendocrine morphology but exhibit immunohistochemical expression of neuroendocrine markers. However, these entities do not fulfill the current diagnostic criteria for MiNEN. In this review, we aim to outline the current diagnostic framework for MiNEN and examine the conceptual and classification boundaries of amphicrine carcinomas and conventional carcinomas with aberrant neuroendocrine marker expression in relation to what is presently defined as a MiNEN. In addition, we highlight key unresolved questions that should be addressed in future guidelines to streamline the diagnostic process and improve consistency. Finally, we provide an outlook on emerging technologies and future perspectives that may further refine the classification and clinical management of these complex neoplasms.
期刊介绍:
Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.